I am a writer and editor of non-fiction books about literature, performance, and music. In my spare time I invest, primarily in microcaps; investigate investment conundrums; and write about my investigations on Seeking Alpha and on my blog, http://backland.typepad.com/investigations. I am now offering a subscription service, The Stock Evaluator, which sends out weekly rankings for over 4,000 stocks; you can reach it here: https://seekingalpha.com/author/yuval-taylor/research.
Paul has been managing Noble Equity Fund, LP, a healthcare-focused hedge fund, since January of 2008. In addition, he manages Noble Advisors, LLC, a Registered Investment Advisor. Prior to this, he worked on the sell side at Sidoti & Co. and Deutsche Bank covering various industries. Mr. Nouri graduated from Rensselaer Polytechnic Institute, in 2005, with a Bachelors of Science in Finance and graduated from Yale School of Management in 2017 with a MBA.
I'm a private, full time trader interested in both long and short ideas. My training and background are in engineering including a decade of consulting engineering practice. I've since switched over to investing/trading which I've done full time for 15+ years and to which I bring a contrarian style. I've also recently become interested in writing and have published editorials at Forbes, PJM, and a few legacy newspapers.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
I invest with passion and conviction, and I have the strength to stick with an investment until my thesis plays out, hence "Courage & Conviction Investing." My greatest gift is a rare ability to synthesize public information on a stock to formulate conclusions the market hasn't even considered. I share this unique skill with subscribers to my Marketplace service, Market Adventures. High-conviction investing isn't for everyone, but if you're in the market to make serious money and you have an insatiable appetite for risk, and you're willing to wait patiently for potentially big gains, then Market Adventures might be the right fit for you.
“When you are inspired by some great purpose, some extraordinary project, all your thoughts break their bonds: Your mind transcends limitations, your consciousness expands in every direction, and you find yourself in a new, great and wonderful world. Dormant forces, faculties and talents become alive, and you discover yourself to be a greater person by far than you ever dreamed yourself to be.” (Author - Patanjali)
“Tentative efforts lead to tentative outcomes. Therefore, give yourself fully to your endeavors. Decide to construct your character through excellent actions and determine to pay the price of a worthy goal. The trials you encounter will introduce you to your strengths. Remain steadfast...and one day you will build something that endures: something worthy of your potential.” (Author - Epictetus)
"Hope sees the invisible, feels the intangible, and achieves the impossible." (Author - Unknown)
"When I stand before God at the end of my life, I would hope that I would not have a single bit of talent left, and could say, 'I used everything you gave me." (Author - Erma Bombeck)
A swing trader by nature, I stick mainly to the big boards stocks under $5. I consider myself still somewhat of a "growing" trader as I have only been actively trading since 2006. The hardest part to overcome has been learning what kind of trader I can be and sticking to that style. I look for certain traits in a stock that could be holding it back and evaluating the risk for a short swing to long term hold. I enjoy helping others in researching a stock they may be looking into and offering ideas of what they may want to look into further. With over 8,000 stocks to choose from there are plenty of fish out there. My analysis is a very basic overview of fundamentals prompted by my interest of how the technical side looks. My picks and my analysis are of my own research and should not be used as investment advice.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
Founder of "The Contrarian", a premium research service, featuring the "Bet The Farm" Portfolio. Actively investing since 1995, I have soared like an eagle, and been unmercifully humbled by the markets. Achieved positive returns in 2008, and turned an account with $60,310 on 1/1/2009 into an account with $3,177,937 on 11/30/2009. My best years have been 1995-2003, 2008-2012, and 2016. My worst years were 2013-2015 & 2017. I believe inflation is coming, and we are at an inflection point in the markets.
Twenty year career as an investment analyst, investor, portfolio manager, consultant, and writer. Founder of Koldus Contrarian Investments, Ltd, which was incorporated in the spring of 2009. Dyed in the wool contrarian investor, who has learned, the hard way, that a good contrarian is only contrarian 20% of the time, but being right at key inflection points is the key to meaningful wealth creation in the markets. I believe we are near a meaningful inflection point, perhaps the biggest one yet, for the third time in the past 15 years.
Historically, I have had huge wins and impressive losses based on a concentrated, contrarian strategy. Trying to keep the good while filtering out the bad.
Seeking to run an all weather portfolio with minimal volatility and index overlays to capture my strategic and tactical recommendations along with a concentrated best ideas portfolio, which is my bread and butter, but the volatility only makes it suitable for a small piece of an investor's overall portfolio. The following are a couple of my favorite investment quotes.
"Life and investing are long ballgames." Julian Robertson
"A diamond is a chunk of coal that is made good under pressure."
"Knowledge is limited. Imagination encircles the world." Albert Einstein
I’ve been on top of the world, and the world has been on top of me. I have learned to enjoy the perspective from each view, and use opportunities to persistently acquire knowledge, and enjoy the company of those around me, especially loved ones, family, and friends.
At heart, I am a market historian with an unrivaled passion for the capital markets. I have had a long history and specialization with concentrated positions and options trading. Made money in 2008 with a net long portfolio, deploying capital in some of the market's darkest hours into long positions including purchases of American Express, Atlas Energy, Crosstex, First Industrial Real Estate, General Growth Properties, Genworth, Macquarie Infrastructure, Ruth Chris Steakhouse, and Vornado near their lows. Shorting, hedging, and option strategies also helped me in 2007 and 2009, and these are skills that I have developed ever since I started trading heavily in 1996.I enjoy reading, accumulating knowledge, and putting this knowledge to work in the active capital markets, learning lessons along the way.To this day, I continue to learn, and some of these learning lessons have been excruciatingly difficult ones, especially over the past several years, as I made mistakes allocating capital, including a sizable portion of my own capital (I always invest alongside my clients), to commodity related stocks. While all commodity related stocks have struggled since April of 2011, coal companies, which attracted me due to their extremely cheap valuations, and out-of-favor status (I am a strong believer in behavioral finance alongside fundamentals and technicals) have been the worst investing mistake of my career. The focus on the commodity arena has been the biggest mistake of my investment career thus far, yet in its aftermath, I see tremendous opportunity, even larger in scope than the fortuitous 2008/2009 environment.The capital that I accumulated and the confidence gained in navigating the treacherous investment waters of 2008 gave me the confidence to launch my own investment firm in the spring of 2009, right before the ultimate lows in the stock market. At the time I was working as a senior analyst at one of the largest RIA's in the country, and I felt strongly that the market environment was the best time since 1974/1975 to start an investment firm.
Prior to starting my firm, I was a senior analyst for three different firms over approximately 10 years (Charles Schwab, Redwood, Oxford), moving up in responsibility and scope at each stop along my journey. Since I was a paperboy, I have always had an interest in the investment markets. I love researching and finding opportunities. I am a Chartered Financial Analyst, CFA, as well as a Chartered Alternative Investment Analyst, CAIA. After starting in the teaching program at Ball State University, I switched to a career in finance when I turned a small student loan into a substantial amount of capital. I graduated summa cum laude with a degree in finance from Ball State.
Full disclosure, I am not currently a registered investment advisor, though I did serve in this capacity from 2009-2014, while owning Koldus Contrarian Investments, Ltd. Additionally, I held various securities licenses from 2000-2014, without a single complaint filed, and I continue to hold industry designations. At the end of 2014, I voluntarily let my state registration expire, as I transitioned the business to a different structure. Prior to this, I had passed, and held, various securities exams and licenses, including the Series 7, Series 63, and Series 65 exams, in addition to others, alongside my CFA and CAIA designations. Unfortunately, I did not file the proper paperwork to withdraw my state registration, and I did not disclose a personal arrangement, and subsequent civil case, between myself and a former close personal friend and client, that was initiated in 2011. I was unaware that I was required to disclose these items, and my securities attorney, at the time, did not advise me to do so. Previously, I had managed a portfolio for this gentleman, and we had taken an investment of approximately $7 million in 2009, and grown it to over $25 million at the beginning of 2012. After a difficult year of performance, an employee of the firm I owned, and friend, resigned in early 2013, and took the aforementioned client to a competing firm. As a result of not filing the proper paperwork, I agreed to a settlement, with a potential $2500 fine in the future, depending on if I choose to reapply to be a non-exempt advisor.
We have investment positions in some of the securities we write about, and our positions are subject to change at any time. Nothing here is to be deemed a solicitation for investment nor investment advice. Please read our full legal disclaimer available on our blog. http://lazarusip.blogspot.com/
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
My name is Mark B. Spiegel and I'm the Managing Member of Stanphyl Capital Management LLC. I can be reached at: mark (at) stanphylcap (dot) com. My Twitter feed is @markbspiegel
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
TheStreetSweeper recently named Sonya Colberg as Senior Editor. About five years ago, she became senior investigative reporter of TheStreetSweeper, a website devoted to exposing fraud, shenanigans and lousy business practices of public companies. Sonya had worked more than two decades as an editor and reporter for two major newspapers, including the recent Warren Buffett acquisition, Tulsa World. Among others, the Associated Press, Great Plains Journalism Awards, The Gerald Loeb Awards and the Society of Professional Journalists have recognized Sonya’s investigative, feature, health, news and business stories. A fearless investigative reporter, Sonya loves nothing better than calling out the shysters and bumblers who quietly work to separate investors from their hard-earned money.
Contact TheStreetSweeper at firstname.lastname@example.org
Jason Bond is an American stock trader, entrepreneur, and small cap expert. Jason teaches small cap swing trading at Jason Bond Picks. He is best known for his 2013 swing trading performance tripling the S&P 500 in the portfolio he manages. Jason’s small cap swing trading ideas are widely published on numerous financial sites and blogs. Prior to teaching small cap swing trading in 2011, Jason taught for the Webster Central School District in NYS from 2001 - 2011. Jason’s trading strategy attempts to capture gains in a stock within one to four days. He uses technical analysis to look for stocks with short-term price momentum. Jason is interested in the fundamental value of stocks but puts emphasis on price trends and patterns.
To all my followers I welcome you to my BlogSpot at SA....
You PAY nothing to me to learn what I know.. I give it to all FREELY and only ask that you pass it on in your own special way, especially if you MAKE MONEY!
I am now nearly 11 years retired from the US pharma industry having spent over 33 years in the Mid-Atlantic Corridor in Sales (Hospital mainly), Scientific Relations, Managed Care/LTC, than back into sales before retiring at age 55! It was always my Dream to retire Early and I achieved my Dream in May of 2007.
I started in 1974 around Christmas Time...US Pharma was the gift that kept giving to me for almost a Lifetime.I began my career 7 months out of College at tiny Reed and Carnrick, Kenilworth, NJ. We had HIGH double digit INFLATION and soaring Un employment in 1974! After 4 years of on the job learning and thank God for Michael Morse the best Division Sales Mgr I ever had, who believed in me when others thought I was too young and In-experienced, I developed into a Solid Pharma sales performer!
Others took notice and came calling in 1978, I left R&C and went to Hospital Sales at BMY for the next 4.5 years, than in 1983 Bayer/Miles Labs recruited me away, I stayed 25 years at Bayer until we merged into SGP/MRK prior to early retirement in 2007..
I was part of the launch of over 50 new drugs over my Career with 6 different Antibiotics including Azlocillin, Amikacin , Cipro and finally Avelox. The list included Antibiotics, Anti-Fungals, Anti High Blood Pressure/ Cholesterol, Anti-Neoplastics/Cancer, Immune Modulators, Dementia/AZ and Diabetes.etc. I like to say I sold drugs that treated people from WOMB to TOMB and I mean that quite literally!
Today I enjoy investing in Bio-Pharmas mostly, because it is what I know best! I come from the Peter Lynch School of Investing so only Invest in what you Know best!
I invest mostly 70% of portfolio in large companies such as AZN, BMY, PFE, MRK, GSK, and JNJ (love the divis and security) but I like the up and coming riskier Bios like EXEL,EXAS,CLDX, ARRY and many others. Cancer, Immunotherapy and Inflammation intrigues me most today--I call these disease states the FRUIT at the Top, pretty much all the Low hanging Fruit is now discovered and available Generically/relatively cheap too....so I have made those 3 Disease States a major Focus since 2008 w/ plays at PFE, JNJ,BMY,MRK and GSK...my best performing BTs are CRIS and EXEL, which have done quite well over time for me....today I see ARRY as a BT that reminds me so much of EXEL or CRIS a couple years ago....I am long ARRY and many others today!
As of 9/20/17 I am announcing a STRONG BUY on CRIS again....a stock Ive been invested in since 2010 w/ net profit booked of ~$68,000. CRIS is One of many incubators for Roche Holdings and Genentech..they are tiny but very nimble and worthy of risk money!
With the real fears of WW Pandemics and MDR-Bacteria, the FDA/Congress has given us BARDA,the GAIN act and QDIP and I've come to appreciate the Retroviral/Antibiotic/Anti-fungal cos.and have made them a major component of my LT strategy to build wealth while in Retirement....
Ive invested in AB cos like Trius(TSRX), Cubist(CBST), Cempra(CEMP-now Melinta), Durata(DRTX), Tetraphase(TTPH), Innovation(IPIX), Akaogen(AKAO),and Paratek(PRTK)....over the last couple years... I manage personal monies and some family members retirement monies..in total well over $1M ....gratis of course!
Just click on my Picture up in the Top left corner and you can always read my thoughts on a myriad of Pharmas and BTs..I think I have 900+ comments going back 10 years now!
I do not write articles for SA because their Editors do not believe in my Writing Style and I'm too old and unwilling to change for them for a lousy $35/article/penny per click payment so I Blog FREE instead! I give FREELY what others charge an ARM or a LEG for and many read me for just that reason, others for my wisdom and yet others for me experiences in Pharma..I try to keep it REAL WORLD when SA imo does not..in fact I think SA is a fraud promoter for much of their operation!
You may or may not agree w/ me in my postings but I will always tell you how I feel about Companies and I spare you the Noise and PC crap you may hear from others...mine is an opine that covers these Companies from the perspective of ONE who worked for/against them and over 33 years..today I am UN-encumbered by the BRIDLES of employment and PC , I can honestly look back at the those who did it right and wrong and share my thoughts w/ you honestly!
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
I hold multiple undergraduate degrees with concentrated focus in the fields of Psychology, Sociology, History, and Economics. Prior to working as an independent strategist for a handful of clients, I was employed as a behavioral economist for a private London based group. Before that, I worked for domestic entities such as FBR and ACC Capital.
In terms of equities analysis, my focus is strictly on long term investments, emerging biotechnology entities, distressed or undervalued companies, and maritime commerce. In terms of market analysis, my focus is on the market implications of social and non-traditional factors. I do not discredit more traditional technical and fundamental analysis, but I value greatly the largely underrated, and often forgotten, historical evolution of capitalism and capital market psychology. Thus, some articles I write will be highly speculative and unorthodox, and will likely represent a minority opinion. Others, when undervaluation is a motivating factor for the article having been written, will be highly technical and metric based.
Also, I urge readers to consider the premise of investment horizon, and authorship intention, when reading my contributions. Many of the articles for companies which I endorse will be deemed "long term", which I generally consider to be no less than 2-3 years unless otherwise noted. Moreover, some articles are written simply to test a potential investment thesis in an effort to garner feedback about prospective positions. In the latter, the "Risk" segment of articles will be thoroughly detailed and should be heavily weighed. Many such pieces will be long "ideas", not necessarily long "recommendations" or "endorsements", and it is imperative that readers understand that prior to any assumptions being made or conclusions being drawn. Thus, I would implore readers to consider my articles carefully and thoroughly, and to ask any questions they may have pertaining to publication purpose if not otherwise clearly defined. I will always do my best to respond in a timely fashion.
Lastly, I am a fervent proponent of the value brought to investments by behavioral finance theory, and I utilize this premise in all equities analysis.
Anonymity Disclosure: I am fully cognizant of the fact that some readers question the integrity and/or accountability of anonymous contributors. Please know that my preference for privacy is a two fold consideration; (1) I remain under a revolving open contract to consult for an entity where I signed a lifetime NCND agreement. In order not to risk violating any potential terms of that agreement, now or in the future, I maintain a very low web based profile. (2) I am a proponent of unbiased analysis being openly shared among prospective investors. However, in order to ensure no collisions occur between professional patronage and personal privacy, I have elected to utilize anonymity as the barrier between the two.
Johnny Duncan is a business writer and analyst of all things profitable. He writes on businesses and industries that can have the greatest positive impact for investors. These include tech, oil and gas, entertainment, and pharmaceutical and medical industries.
John Hodge is an active trader who follows the technology/biotech sector specifically. I have been successfully trading stocks for the last 16 years and still thank those that pointed me in the direction of Qualcomm and Amgen many years ago. I believe research and timing is the key to long term goal attainment in the market.